Midgard Science

Labs / CDMO: development & manufacturing

Antag Therapeutics

Copenhagen, Denmark · antagtx.com

GLP

Antag Therapeutics develops first-in-class GIP receptor antagonist therapies for obesity, diabetes, and overweight. The company is based in Copenhagen, Denmark, and focuses on metabolic disease drug development and clinical-stage programs. It welcomes collaborators, investors, and scientific partners interested in its approach to obesity treatment.

They take quote requests by email.

What they offer

  • GIP receptor antagonism therapy development

    Develops therapies based on GIP receptor antagonism for obesity and metabolic disease.

  • Clinical-stage drug development

    Advances AT-7687 as a clinical-stage candidate and evaluates it in clinical studies.

  • Combination therapy development

    Investigates AT-7687 both as monotherapy and in combination with other obesity therapies.

What they work on

Modalities
Peptide
Species and models
Non-human primate
Therapeutic areas
obesity, diabetes, overweight, metabolic disease, cardiometabolic disease
Minimums and prices
€80 million Series A financing
Sites
Copenhagen, Denmark

Similar labs. 3C Therapeutics, Alcami, Alphalyse, Arcinova

Found in a contract services directory. Listing built from antagtx.com. Work here? Claim this listing.

Antag Therapeutics · Midgard Science